Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODORAT: Optimal dose of anti-lymphocyte globulin in kidney transplant recipients with low immunological risk
2024-514792-17-00Phase 2Authorised
- Sponsor
- CHRU Nancy
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of antithymocyte globulin rabbit in Kidney allograft status (RTx) and end-stage kidney disease (ESKD) (2 arms), sponsored by CHRU Nancy. Primary endpoint: Dose-limiting toxicity defined by T cell depletion. Planned start Oct 2024; status: authorised.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
Kidney allograft status (RTx)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2024-514792-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514792-17-00.